10th Jan 2012 18:32
This announcement replaces the original announcement released on 3 January 2012 at 15.50 (RNS No: 9230U)
Due to an administrative error the change in one of the Non-Executive Director's interests in the American Depositary Shares (ADSs) of GlaxoSmithKline plc indicated with an asterisk (*) below, was incorrectly stated in the announcement made on 3 January 2012.
Save as disclosed above, all other details remain unchanged. The full amended text is shown below.
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the directors' interests in the Ordinary shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.
On 30 December 2011, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares at a price of £14.70 per Ordinary share and $45.53 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 October 2011 to 30 December 2011:
Non Executive Director | Ordinary Shares | American Depositary Shares (ADSs) |
Sir Christopher Gent | 2,295.918 | |
Prof. Sir Roy Anderson | 573.980 | |
| ||
Dr Stephanie Burns | 325.294 | |
Ms Stacey Cartwright
| 318.878 | |
Mr Lawrence Culp | 650.588 | |
Sir Crispin Davis | 2,125.850 | |
Ms Judy Lewent
| 162.647* | |
Sir Deryck Maughan | 650.588 | |
Mr James Murdoch | 1,275.510 | |
Dr Daniel Podolsky | 683.117 | |
Mr Tom de Swaan | 786.565 | |
Sir Robert Wilson | 573.980 |
The Company and the Non-Executive Directors were informed of these allocations on
3 January 2012.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
10 January 2012
Related Shares:
Glaxosmithkline